Consultation record

Submissions accepted — page 24

The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission.

Submissions

735 documents · page 24 of 25

Table 1. Submissions with this disposition, on this page.

Reference	Consultation	Respondent	Point raised
DRAFT-RUSSIAN-REGI/012	Draft synthesis: Nationally registered neuropeptides and the…	Dr Melisande Kirkpatrick-Ola	Absence of evidence is presented in a form a reader will take as negative evidence
DRAFT-RUSSIAN-REGI/014	Draft synthesis: Nationally registered neuropeptides and the…	Dr Ndidi Ravensworth-Ilunga	Registered trials that never reported are not counted anywhere in the review
DRAFT-RUSSIAN-REGI/015	Draft synthesis: Nationally registered neuropeptides and the…	Thaddeus Isaksen-Balogun	The timepoint at which each outcome was extracted was chosen after the data were seen
DRAFT-SPONSOR-COND/002	Draft synthesis: The consequences of a wholly sponsor-generated…	Anselm Mountstephen	The search strategy as published cannot be re-run
DRAFT-SPONSOR-COND/005	Draft synthesis: The consequences of a wholly sponsor-generated…	Dr Vittoria Quintanilha	Registered trials that never reported are not counted anywhere in the review
DRAFT-SPONSOR-COND/006	Draft synthesis: The consequences of a wholly sponsor-generated…	Dr Oisín Rautavaara	Overlapping primary studies across included reviews are counted more than once
DRAFT-SPONSOR-COND/009	Draft synthesis: The consequences of a wholly sponsor-generated…	Dr Ndidi Ravensworth-Ilunga	Risk-of-bias judgements are reported as an overall rating without the domains
DRAFT-SURROGATE-OU/004	Draft synthesis: Percentage weight change as a surrogate outcome	Dr Constança Glendinning-Uche	The same concept is given three different names in one document
DRAFT-SURROGATE-OU/005	Draft synthesis: Percentage weight change as a surrogate outcome	Dr Oisín Rautavaara	Overlapping primary studies across included reviews are counted more than once
DRAFT-SURROGATE-OU/007	Draft synthesis: Percentage weight change as a surrogate outcome	Dr Lorcan Zaleski-Mbeki	Efficacy outcomes are rated for certainty and harms are not
DRAFT-SURROGATE-OU/008	Draft synthesis: Percentage weight change as a surrogate outcome	Dr Kolawole Isaksen-Balogun	Intention-to-treat and efficacy-estimand results are combined without distinction
DRAFT-SURROGATE-OU/009	Draft synthesis: Percentage weight change as a surrogate outcome	Dr Leonhard Quenneville	Doses differing several-fold are pooled without examining dose-response
DRAFT-AMYLIN-ANALO/001	Draft synthesis: Amylin analogues as monotherapy and in combination	Dr Theodora Ingelbrecht	Doses differing several-fold are pooled without examining dose-response
DRAFT-AMYLIN-ANALO/002	Draft synthesis: Amylin analogues as monotherapy and in combination	Dr Melisande Thorsby-Nakamura	Analytical surveys are treated as evidence about suppliers when they establish only what was in a…
DRAFT-AMYLIN-ANALO/004	Draft synthesis: Amylin analogues as monotherapy and in combination	Dr Evander Ashworth-Danquah	An indirect comparison is presented without an assessment of transitivity
DRAFT-AMYLIN-ANALO/009	Draft synthesis: Amylin analogues as monotherapy and in combination	Quentin Whitmarsh-Obi	The review does not say when it will be updated or what would trigger an update
DRAFT-DISCONTINUED/001	Draft synthesis: Discontinued development programmes as evidence	Dr Delphine Trelawney	Doses differing several-fold are pooled without examining dose-response
DRAFT-DISCONTINUED/002	Draft synthesis: Discontinued development programmes as evidence	Dr Kolawole Isaksen-Balogun	A funnel plot is presented for a set too small to interpret it
DRAFT-DISCONTINUED/003	Draft synthesis: Discontinued development programmes as evidence	Dr Leonhard Quenneville	The comparator was given at a dose below the one in general use
DRAFT-RECONSTITUTI/001	Draft synthesis: Reconstitution practice and delivered dose	Dr Odalys Thorsby-Nakamura	The sampling frame of each contributing survey is not reported
DRAFT-RECONSTITUTI/002	Draft synthesis: Reconstitution practice and delivered dose	Dr Anselm Thorsby-Nakamura	Results obtained by different methods are pooled without recording the method
DRAFT-RECONSTITUTI/003	Draft synthesis: Reconstitution practice and delivered dose	Dr Jozef Brandvold-Achterberg	Risk-of-bias judgements are reported as an overall rating without the domains
DRAFT-PANCREATITIS/001	Draft synthesis: Acute pancreatitis with incretin-based therapies	Dr Kolawole Isaksen-Balogun	A single-trial result is presented in the visual form of a pooled estimate
DRAFT-PANCREATITIS/003	Draft synthesis: Acute pancreatitis with incretin-based therapies	Dr Zdenka Nyquist-Obiora	Doses differing several-fold are pooled without examining dose-response
DRAFT-PANCREATITIS/006	Draft synthesis: Acute pancreatitis with incretin-based therapies	Dr Ivo Quintanilha	Results at materially different follow-up durations are pooled
DRAFT-PANCREATITIS/010	Draft synthesis: Acute pancreatitis with incretin-based therapies	Dr Yaa Kettlewell	The timepoint at which each outcome was extracted was chosen after the data were seen
DRAFT-ENDOTOXIN-IN/001	Draft synthesis: Bacterial endotoxin in research-supply peptide…	Dr Adaeze Underhill-Okafor	The sampling frame of each contributing survey is not reported
DRAFT-PRIMARY-VS-S/001	Draft synthesis: Cardiovascular benefit in primary compared with…	Dr Oisín Rautavaara	A single-trial result is presented in the visual form of a pooled estimate
DRAFT-PRIMARY-VS-S/002	Draft synthesis: Cardiovascular benefit in primary compared with…	Dr Jerome Petrossian	An indirect comparison is presented without an assessment of transitivity
DRAFT-PRIMARY-VS-S/005	Draft synthesis: Cardiovascular benefit in primary compared with…	Dr Melisande Kirkpatrick-Ola	Results at materially different follow-up durations are pooled

page 24 of 25